Insilico Medicine Secures $110 Million in Series E Funding
2025-03-13 / Read about 0 minute
Author:小编   

On March 13th, Insilico Medicine triumphantly announced the successful completion of its Series E funding round, securing a substantial investment of $110 million. This round was co-led by an esteemed group of investors, including the private equity fund of Value Partners Group, Pudong Venture Capital, Pudong Development Bank Group, Wuxi Venture Capital, and Yixing State-Owned Assets Investment Holding Group. The influx of funds will strategically bolster Insilico Medicine's endeavors to refine its AI models and algorithms, enhance its state-of-the-art automated robotic laboratory, propel forward the clinical validation of its leading drug candidate for idiopathic pulmonary fibrosis, and expedite the exploration of additional self-developed and collaboratively developed drug pipelines.